Vanguard Group Inc. Purchases 68,151 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Vanguard Group Inc. raised its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,824,212 shares of the company's stock after buying an additional 68,151 shares during the quarter. Vanguard Group Inc. owned 5.29% of Zevra Therapeutics worth $23,554,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Zevra Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company's stock worth $842,000 after acquiring an additional 11,038 shares in the last quarter. State Street Corp lifted its holdings in shares of Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company's stock valued at $5,363,000 after buying an additional 52,966 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $94,000. Barclays PLC raised its position in Zevra Therapeutics by 292.6% during the third quarter. Barclays PLC now owns 57,599 shares of the company's stock valued at $399,000 after acquiring an additional 42,926 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company's stock valued at $7,246,000 after acquiring an additional 129,600 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ZVRA shares. Canaccord Genuity Group raised their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $22.29.

Insider Activity at Zevra Therapeutics

In other news, Director John B. Bode bought 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The stock was acquired at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the purchase, the director now owns 40,000 shares of the company's stock, valued at $318,400. This trade represents a 33.33 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the transaction, the executive vice president now directly owns 29,486 shares of the company's stock, valued at approximately $231,759.96. This trade represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 85,773 shares of company stock worth $674,176. Company insiders own 2.40% of the company's stock.

Zevra Therapeutics Stock Performance

Shares of ZVRA traded up $0.10 during mid-day trading on Friday, hitting $7.15. The company's stock had a trading volume of 406,058 shares, compared to its average volume of 606,022. The stock's 50-day moving average is $7.60 and its two-hundred day moving average is $8.15. The firm has a market capitalization of $386.93 million, a PE ratio of -3.63 and a beta of 1.94. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. As a group, sell-side analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.